5.65

4.05% 0.22

After Hours: 5.63 -0.02 -0.35%

Plus Therapeutics Inc (PSTV)

Overview News Price History Financials Discussions Forecast Stock Split

Plus Therapeutics Inc stock is traded at $5.65, with a volume of 473.67K. It is up +4.05% in the last 24 hours and up +2,160% over the past month. Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Previous Close:

$5.43

Open:

$5.54

24h Volume:

473.67K

Relative Volume:

0.05

Market Cap:

$38.77M

Revenue:

$5.21M

Net Income/Loss:

$-26.35M

P/E Ratio:

-0.1761

EPS:

-32.0862

Net Cash Flow:

$-20.84M

1W Performance:

+78.23%

1M Performance:

+2,160%

6M Performance:

+730.88%

1Y Performance:

+767.90%

1-Day Range:

$5.24

$6.05

1-Week Range:

$3.13

$6.05

52-Week Range:

$0.129

$6.05

Plus Therapeutics Inc Stock (PSTV) Company Profile

Name

Plus Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

737.255.7194

Address

4200 MARATHON BLVD., AUSTIN, TX

Employee

Twitter

@plustxinc

Next Earnings Date

2026-03-26

Latest SEC Filings

PSTV's Discussions on Twitter

Compare PSTV vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PSTV Plus Therapeutics Inc	5.65	37.26M	5.21M	-26.35M	-20.84M	-32.09
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-03-26	Initiated	Lake Street	Buy
Sep-03-25	Upgrade	D. Boral Capital	Hold → Buy
Mar-17-25	Initiated	D. Boral Capital	Buy
Jan-25-21	Initiated	Ladenburg Thalmann	Buy
Oct-16-20	Initiated	Maxim Group	Buy

Plus Therapeutics Inc Stock (PSTV) Latest News

Apr 15, 2026

Plus Therapeutics appoints Randy Goodman to lead market access By Investing.com - Investing.com Australia

Apr 15, 2026

Plus Therapeutics Hires Randy Goodman to Lead Market Access and Value Strategy - citybiz

Apr 15, 2026

Plus Therapeutics appoints Randy Goodman to lead market access - Investing.com

Apr 15, 2026

Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution - The Manila Times

Apr 15, 2026

Apr 14, 2026

Plus Therapeutics secures FDA orphan drug status for pediatric glioma treatment - MSN

Apr 14, 2026

PSTV stock on track for best week since September — here’s what is driving the rally - MSN

Apr 14, 2026

Why is Plus Therapeutics stock gaining Friday? - MSN

Apr 14, 2026

Apr 13, 2026

PSTV Stock On Track For Best Week Since September — Here’s What Is Driving The Rally - Stocktwits

Apr 13, 2026

Trend Report: What are the analyst revisions for Plus Therapeutics IncIs VRSN stock a good investment in YEARMarket Sentiment Review & Community Verified Watchlist Alerts - baoquankhu1.vn

Apr 13, 2026

Apr 10, 2026